Atopix Therapeutics
Abingdon
About Atopix Therapeutics
Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK, with an innovative approach to allergy. The company is developing a novel class of oral anti-allergic medicines, called CRTH2 antagonists, to treat atopic dermatitis, asthma and allergic rhinitis. Its lead candidate is currently being studied in a Phase 2 clinical trial for moderate to severe atopic dermatitis in several leading European dermatology centres.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.5M
- Funding stage: M&A
- Last round: Series Unknown (Nov 2016)
- Website: atopixtherapeutics.co.uk
- Phone: +44 (0) (440) 123-5841
Industries & Categories
Biotechnology, Life Science, Medical
Canonical: https://fsome.com/organization/atopix-therapeutics-2704982 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.